首页 > 市场调查报告书 > 製药

个人化医学

市场调查报告书

商品编码

1524341

精准医疗市场- 应用（诊断[基于基因、生物标记的测试]、治疗[抑制剂药物、单株抗体]）、适应症（肿瘤学、中枢神经系统）、技术（基因组学、生物资讯学）、最终用户- 全球预测（2024 年- 2032 年）

Precision Medicine Market - Application (Diagnostics [Genetic, Biomarker Based Tests], Therapeutics [Inhibitor Drugs, Monoclonal Antibodies]), Indication (Oncology, CNS), Technology (Genomics, Bioinformatics), End-user - Global Forecast (2024 - 2032)

出版日期: 2024年04月30日 | 出版商:

Global Market Insights Inc. | 英文 234 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在研究机构、製药公司和医疗保健提供者之间不断加强的合作伙伴关係的推动下，精准医疗市场规模预计 2024 年至 2032 年间复合年增长率将达到 7.6%。这些努力正在加速针对个人基因图谱和病史的个人化治疗的发展。同时，政府的措施和资金正在支持这些合作，以促进研究突破并扩大创新疗法的可及性。

精准医疗强调巨量资料分析和人工智慧的整合，以提高诊断准确性和治疗效果，其重要性日益凸显，这将有利于产业的成长。例如，2023 年 10 月，欧洲个人化医疗伙伴关係在巴伦西亚的一次高级别会议上启动。该措施旨在推动精准医疗，以促进创新并在整个欧洲卫生系统中整合个人化医疗解决方案。

该行业根据应用、适应症、技术、最终用户和地区进行细分。

由于越来越多地采用基因检测和分子分析以根据患者个体特征量身定制治疗方法，诊断应用领域的精准医疗市场份额预计将在 2032 年大幅增长。这些应用程式使医疗保健提供者能够更早、更准确地诊断疾病，从而改善患者的治疗结果。此外，诊断工具与人工智慧和机器学习等先进技术相结合，以增强诊断的预测能力，使临床医生能够预测疾病进展并推荐个人化介入。

在技术方面，随着医疗保健提供者正在分析大量患者资料以製定个人化治疗计划，巨量资料分析领域的精准医疗行业预计将在 2024 年至 2032 年期间产生可观的收入。这项技术能够整合基因组资讯、医疗记录和生活方式资料，以发现模式和相关性，从而为精确的医疗干预提供资讯。研究人员和临床医生也利用巨量资料分析来识别遗传倾向、预测治疗反应并改善疾病管理策略。

由于慢性病盛行率上升以及对个人化癌症治疗的需求不断增加，欧洲精准医疗产业规模到 2032 年可能会显着增长。精准医学计画正在整合基因组资料和分子分析，为个别患者量身定制治疗方案，以改善治疗结果和患者的生活品质。对新生物标记和治疗标靶的持续探索，利用正在进行的研究来开发更精确的诊断工具和标靶治疗，将推动区域市场的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 已开发地区癌症生物学的进展
  - 扩大精准医疗药物组合
  - 越来越多采用基因疗法
- 产业陷阱与挑战
  - 精准医疗成本高
  - 严格的监理规范
成长潜力分析
管道分析
未来市场趋势
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按应用划分，2021 - 2032 年

主要趋势
诊断
- 基因测试
- 基于生物标誌物的测试
- 深奥的测试
- 其他测试
疗法
- 抑制剂药物
- 单株抗体
- 细胞与基因治疗
- 抗病毒和抗逆转录病毒药物
- 其他疗法

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

主要趋势
肿瘤学
中枢神经系统疾病
免疫学
呼吸疾病
遗传性疾病
皮肤病
其他适应症

第 7 章：市场估计与预测：按技术分类，2021 - 2032

主要趋势
基因组学
生物资讯学
巨量资料分析
生物标记检测
高通量筛选
其他技术

第 8 章：市场估计与预测：按最终用户分类，2021 - 2032 年

主要趋势
医院
诊断实验室
其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Abbott Laboratories, Inc.
Abbvie, Inc.
AstraZeneca plc
bioMerieux SA
Bristol-Myers Squibb Company
Cepheid (Danaher Corporation)
Eli Lilly & Company
F. Hoffmann-La Roche
GlaxoSmithKline plc
Laboratory Corporation of America Holdings (Covance Inc.)
Myriad Genetics, Inc.
Novartis AG
Pfizer, Inc.
QIAGEN N.V.
Quest Diagnostics
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vyant Bio, Inc. (Cancer Genetics, Inc.)

简介目录

Product Code: 671

Precision Medicine Market size is expected to record 7.6% CAGR between 2024 and 2032, driven by rising partnerships between research institutions, pharmaceutical companies, and healthcare providers. These efforts are accelerating the development of personalized treatments tailored to individual genetic profiles and medical histories. Simultaneously, government initiatives and funding are supporting these collaborations for fostering research breakthroughs and expanding access to innovative therapies.

The surging importance of precision medicine for emphasizing the integration of big data analytics and AI to enhance diagnostic accuracy and treatment outcomes will favor the industry growth. For instance, in October 2023, the European Partnership for personalized medicine was launched in Valencia at a high-level conference. This initiative aimed at advancing precision medicine for fostering innovations and integrating personalized healthcare solutions across European health systems.

The industry is segmented based on application, indication, technology, end-user, and region.

Precision medicine market share from the diagnostics application segment is expected to witness substantial growth through 2032, backed by the rising adoption of genetic testing and molecular profiling to tailor treatments based on individual patient characteristics. These applications are enabling healthcare providers to diagnose diseases earlier and with greater accuracy for improving patient outcomes. In addition, diagnostic tools are incorporated with advanced technologies, such as AI and machine learning to enhance predictive capabilities of diagnostics for enabling clinicians to anticipate disease progression and recommend personalized interventions.

In terms of technology, the precision medicine industry from the big data analytics segment is slated to generate notable revenue during 2024-2032 as healthcare providers are analyzing vast amounts of patient data to personalize treatment plans. This technology is enabling the integration of genomic information, medical records, and lifestyle data to uncover patterns and correlations that inform precise medical interventions. Researchers and clinicians are also harnessing big data analytics to identify genetic predispositions, predict treatment responses, and improve disease management strategies.

Europe precision medicine industry size is likely to record a notable growth rate through 2032 driven by the rising prevalence of chronic diseases and the increasing demand for personalized cancer therapeutics. Precision medicine initiatives are integrating genomic data and molecular profiling to customize therapies for individual patients to improve treatment outcomes and patient quality of life. The growing exploration of new biomarkers and therapeutic targets for leveraging ongoing research to develop more precise diagnostic tools and targeted therapies will drive the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Advancements in cancer biology in developed region
  - 3.2.1.2 Expanding portfolio of precision medicine drugs
  - 3.2.1.3 Increasing adoption of gene therapy
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of precision medicine
  - 3.2.2.2 Stringent regulatory norms
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Future market trends
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diagnostics
- 5.2.1 Genetic tests
- 5.2.2 Biomarker based tests
- 5.2.3 Esoteric tests
- 5.2.4 Other tests
5.3 Therapeutics
- 5.3.1 Inhibitor drugs
- 5.3.2 Monoclonal antibodies
- 5.3.3 Cell & gene therapy
- 5.3.4 Antiviral & anti-retroviral drugs
- 5.3.5 Other therapeutics

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oncology
6.3 CNS disorders
6.4 Immunology
6.5 Respiratory diseases
6.6 Genetic disorders
6.7 Skin diseases
6.8 Other indications

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Genomics
7.3 Bioinformatics
7.4 Big data analytics
7.5 Biomarker detection
7.6 High throughput screening
7.7 Other technologies

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Diagnostic laboratories
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa